BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35933487)

  • 21. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    Gao ZH; Li CX; Liu M; Jiang JY
    BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
    Kim YJ; Kim JS; Kim IA
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
    Falck AK; Fernö M; Bendahl PO; Rydén L
    BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA aneuploidy identifies a subset of Luminal subtype breast carcinoma patients with worse clinical outcome.
    Pinto AE; Matos J; Pereira T; Silva GL; André S
    Pathol Res Pract; 2023 Jun; 246():154513. PubMed ID: 37167811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
    Witzel I; Laakmann E; Weide R; Neunhöffer T; Park-Simon TJ; Schmidt M; Fasching PA; Hesse T; Polasik A; Mohrmann S; Würschmidt F; Schem C; Bechtner C; Würstlein R; Fehm T; Möbus V; Burchardi N; Loibl S; Müller V
    Eur J Cancer; 2018 Oct; 102():1-9. PubMed ID: 30099223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
    Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
    Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
    Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
    Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
    Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
    Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparametric MRI Features of Breast Cancer Molecular Subtypes.
    Szep M; Pintican R; Boca B; Perja A; Duma M; Feier D; Fetica B; Eniu D; Dudea SM; Chiorean A
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term survival analysis of different breast cancer molecular subtypes: Shanghai Breast Cancer Survival Study].
    Bao P; Peng P; Gu K; Wu C; Huang Z; Gong Y; Zhang M; Zheng Y
    Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):928-34. PubMed ID: 26850665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database.
    Tang Z; Li L; Huang X; Zhao Y; Huang L
    Breast Cancer; 2024 Mar; 31(2):205-216. PubMed ID: 38043116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer.
    Howland NK; Driver TD; Sedrak MP; Wen X; Dong W; Hatch S; Eltorky MA; Chao C
    J Surg Res; 2013 Dec; 185(2):697-703. PubMed ID: 24095025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
    BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.